CONJUGATE VACCINE ON BASIS OF ANTIGEN WT1 PEPTIDE Russian patent published in 2018 - IPC C07K7/06 C07K7/08 A61K38/08 A61K39/00 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a compound of formula (1), wherein X^a and Y^a each represents a single bond, peptide A of a cancer antigen is a peptide consisting of an amino acid sequence RMFPNAPYL (SEQ ID NO: 2), the amino group of the N-terminal amino acid of the peptide A of the cancer antigen is attached to Y^a in the formula (1) and the carbonyl group of the C-terminal amino acid of peptide A of the cancer antigen is attached to the hydroxyl group in formula (1), R¹ is a peptide C of a cancer antigen, peptide C of the cancer antigen has a sequence different from that of the cancer antigen A peptide that is a peptide consisting of any amino acid sequence selected from the amino acid sequences shown below: CMTWNQMNL (SEQ ID NO: 3) and CYTWNQMNL (SEQ ID NO: 4), and the thioester group of the cysteine residue of peptide C of the cancer antigen is attached to the thioester group in formula (1), or a pharmaceutically acceptable salt thereof.

(1).

EFFECT: compounds of formula (1) may find use in the preparation of a vaccine against cancer associated with the expression of the WT1 gene.

20 cl, 27 dwg, 71 tbl, 19 ex